基因组 - 分子时代乳腺癌合并急性髓系白血病的适宜临床策略：一例报告
Appropriate Clinical Strategies for Breast Cancer Coexisting with Acute Myeloid Leukemia in the Genomic-Molecular Era: A Case Report.
作者信息
Hu Guangfu, Mallik Dipendra K, Yang Weige, Hou Yingyong, Cheng Zhixiang, Chen Pu, Zhu Wei, Wang Hong, Shen Lei, Zhang Hongwei, Yang Ziang
机构信息
Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
出版信息
Breast Care (Basel). 2016 Apr;11(2):145-7. doi: 10.1159/000443494. Epub 2016 Feb 8.
BACKGROUND
The coexistence of breast cancer (BC) and acute myeloid leukemia (AML) has rarely been reported. Considering the fatality of AML, the management of this condition is based on treating the AML immediately while putting BC treatment on hold.
CASE REPORT
Here, we report a synchronous occurrence of BC and AML. Prognostic factors for both BC and AML were determined by genomic and molecular evaluation. The evaluation for AML showed a relatively good prognosis, and we simultaneously conducted treatment for AML and BC. The patient has survived for more than 3 years, which makes this the case with the longest survival reported.
CONCLUSION
In patients with BC and AML, it is essential to determine the prognosis through a genomic and molecular evaluation. For a certain group of patients whose prognosis of AML is good, simultaneous or initial treatment of BC before treatment of AML may be appropriate.
背景
乳腺癌（BC）与急性髓系白血病（AML）并存的情况鲜有报道。鉴于AML的致死性，这种情况的治疗是在暂停BC治疗的同时立即治疗AML。
病例报告
在此，我们报告一例BC与AML同时发生的病例。通过基因组和分子评估确定了BC和AML的预后因素。对AML的评估显示预后相对良好，我们同时对AML和BC进行了治疗。该患者已存活超过3年，这是报道中存活时间最长的病例。
结论
对于患有BC和AML的患者，通过基因组和分子评估来确定预后至关重要。对于AML预后良好的特定患者群体，在治疗AML之前同时或先治疗BC可能是合适的。
Zotero 插件